P

Pear Therapeutics Inc
NASDAQ:PEAR

Watchlist Manager
Pear Therapeutics Inc
NASDAQ:PEAR
Watchlist
Price: 0.0077 USD -15.38% Market Closed
Updated: May 19, 2024

Gross Margin
Pear Therapeutics Inc

41.8%
Current
-11%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
41.8%
=
Gross Profit
5.3m
/
Revenue
12.7m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Pear Therapeutics Inc
NASDAQ:PEAR
1.1m USD
42%
US
Veeva Systems Inc
NYSE:VEEV
33.9B USD
71%
US
Cerner Corp
NASDAQ:CERN
27.9B USD
83%
US
Change Healthcare Inc
NASDAQ:CHNG
9B USD
59%
AU
Pro Medicus Ltd
ASX:PME
12.2B AUD
100%
JP
M3 Inc
TSE:2413
1.1T JPY
59%
US
Doximity Inc
NYSE:DOCS
5.2B USD
89%
US
Inspire Medical Systems Inc
NYSE:INSP
4.6B USD
85%
SE
Sectra AB
STO:SECT B
45.6B SEK
49%
US
Goodrx Holdings Inc
NASDAQ:GDRX
2.8B USD
92%
US
Vocera Communications Inc
NYSE:VCRA
2.8B USD
66%
P
Pear Therapeutics Inc
NASDAQ:PEAR
Country US
Market Cap 1.1m USD
Gross Margin
42%
Veeva Systems Inc
NYSE:VEEV
Country US
Market Cap 33.9B USD
Gross Margin
71%
Cerner Corp
NASDAQ:CERN
Country US
Market Cap 27.9B USD
Gross Margin
83%
Change Healthcare Inc
NASDAQ:CHNG
Country US
Market Cap 9B USD
Gross Margin
59%
Pro Medicus Ltd
ASX:PME
Country AU
Market Cap 12.2B AUD
Gross Margin
100%
M3 Inc
TSE:2413
Country JP
Market Cap 1.1T JPY
Gross Margin
59%
Doximity Inc
NYSE:DOCS
Country US
Market Cap 5.2B USD
Gross Margin
89%
Inspire Medical Systems Inc
NYSE:INSP
Country US
Market Cap 4.6B USD
Gross Margin
85%
Sectra AB
STO:SECT B
Country SE
Market Cap 45.6B SEK
Gross Margin
49%
Goodrx Holdings Inc
NASDAQ:GDRX
Country US
Market Cap 2.8B USD
Gross Margin
92%
Vocera Communications Inc
NYSE:VCRA
Country US
Market Cap 2.8B USD
Gross Margin
66%

Profitability Report

View the profitability report to see the full profitability analysis for Pear Therapeutics Inc.

Full Profitability Report

See Also

Summary
PEAR intrinsic value, competitors valuation, and company profile.
DCF Valuation
PEAR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PEAR stock valuation using valuation multiples.
Wall Street Estimates
PEAR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PEAR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
41.8%
=
Gross Profit
5.3m
/
Revenue
12.7m
What is the Gross Margin of Pear Therapeutics Inc?

Based on Pear Therapeutics Inc's most recent financial statements, the company has Gross Margin of 41.8%.

ALPHA SPREAD
Join more than 138,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.